PGx Panels for Research Studies
From discovery through clinical later phase clinical trials, the utilization of pharmacogenomic approaches is an evolving and valuable process. Early phase data on genomic-dependent dosing or efficacy can provide guidance on dosing or patient selection in later phase trials, saving valuable time and money when conducting a study. GnomeDx has the ability to screen your study’s potential candidates with several validated single nucleotide polymorphisms (SNPs) assays, with relevance to drug classes in the areas of:
- Cardiac
- Psychiatric
- Pain
- Custom